Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis’ ...

Core Viewpoint - AgEagle Aerial Systems, Inc. has experienced a significant decline in stock performance despite reporting improved profitability metrics for the first quarter of 2025, indicating investor caution due to concerns over revenue growth and reliance on non-operational gains [1][12]. Revenue & Earnings Performance - For Q1 2025, AgEagle reported revenues of $3.65 million, a decrease of 6.3% from $3.89 million in Q1 2024, attributed to seasonality in sensor sales and the discontinuation of SaaS operations [2] - The company achieved a net income of $7.06 million, a substantial increase of 211.8% from a net loss of $6.32 million a year ago, primarily due to a $7.78 million non-cash gain from the change in fair value of warrant liabilities [3] Other Key Business Metrics - Gross profit increased by 9.2% to $2.13 million from $1.95 million year-over-year, with gross margin improving to 58.5% from 50.2%, driven by a favorable product mix, particularly in higher-margin drone sales, which surged 98.4% to $2.23 million [4] - Operating expenses decreased by 27.9% year-over-year to $3.14 million, leading to a narrowed operating loss of 58.1% to $1 million from $2.4 million in the prior-year quarter [5] Management Commentary - CEO Bill Irby described the quarter as a "pivotal milestone," highlighting improvements in gross margin and significant reductions in operating expenses as indicators of a more focused operational strategy [6] Factors Influencing Results - The net income increase was significantly supported by the revaluation of warrant liabilities, contributing $7.78 million to the bottom line, while the exit from SaaS operations reduced revenues but also eliminated associated costs [7] Other Developments - AgEagle leveraged a funding agreement with Alpha Capital Anstalt, receiving $1.5 million in preferred equity through two tranches in February and March 2025, which resulted in $1.06 million in deemed dividends due to down-round provisions [9] - Following the quarter, AgEagle amended the Series B Warrant terms and appointed a new CFO, Alison Burgett, effective April 14, 2025 [10] - On May 5, 2025, Alpha invested an additional $0.5 million for Series F shares convertible into 602,846 shares of common stock, reinforcing AgEagle's capital base [11]

AstraZeneca (AZN) stock has declined 6.4% in the past three months.Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market uncertainties and a volatile macroeconomic environment.The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets. Though the massive tariffs imposed by the United States and China are now on a pause, it is only a temporary suspension, and no ...

Core Viewpoint - Amgen's stock has faced a decline of 10.4% over the past three months, largely attributed to macroeconomic uncertainties and trade tensions [1][2]. Group 1: Market Environment - The stock market has experienced volatility due to President Trump's tariffs and China's retaliatory measures, although a recent deal has eased tensions temporarily [2]. - The uncertainty surrounding tariffs continues to impact economic growth, despite pharmaceuticals being exempt from initial tariffs [3]. Group 2: Company Performance - Amgen's revenues grew by 9% year over year in Q1 2025, driven by increased patient demand for innovative medicines [4]. - The company is facing declining revenues from oncology biosimilars and established products like Enbrel, with competitive pressures affecting sales [5]. - Key revenue drivers include older medicines like Prolia and Repatha, as well as new drugs such as Tavneos and Tezspire, alongside rare disease drugs from the acquisition of Horizon Therapeutics [5]. Group 3: Drug Pipeline and Approvals - Amgen is evaluating several drugs for additional indications, which could enhance revenue growth, with Uplizna recently approved for IgG4-related disease [6][7]. - The company has invested significantly in M&A to diversify its pipeline, including the development of MariTide, a novel obesity treatment [8][10]. - Clinical studies for MariTide have shown promising results, and further studies are ongoing [9][10]. Group 4: Biosimilars and Market Strategy - Amgen launched several new biosimilars in 2025, generating substantial sales, including Wezlana and Pavblu, which contributed to a 35% year-over-year increase in biosimilar sales [13][15]. - The company is actively pursuing additional biosimilar approvals to mitigate the impact of upcoming patent expirations for key drugs [15][16]. Group 5: Financial Outlook - Amgen's stock has outperformed the industry and S&P 500, with a year-to-date increase of 7.3% [18]. - The stock is reasonably valued, trading at a price/earnings ratio of 13.12, lower than the industry average [21]. - Earnings estimates for 2025 and 2026 have seen upward revisions, indicating positive market sentiment [24][26]. Group 6: Long-term Growth Potential - The company is expected to maintain long-term revenue growth driven by strong performance from key drugs and innovative medicines [27]. - Despite initial data from MariTide studies being below expectations, it holds potential as a significant product for Amgen [27].

Core Viewpoint - Home Depot is committed to maintaining stable prices despite tariff pressures, contrasting with competitors like Walmart who may need to raise prices due to increased costs from tariffs [1][4]. Group 1: Home Depot's Strategy - Home Depot is actively working with suppliers to shift production away from China and is negotiating for price concessions to protect consumers from the trade war's impact [1]. - The company's CFO, Richard McPhail, stated that no single country outside the U.S. will account for more than 10% of their purchases in the next 12 months [2]. - Home Depot has not altered its financial forecast for 2025, reporting a 0.2% increase in U.S. comparable sales and a 2.1% rise in customer transactions to 394.8 million [3]. Group 2: Competitive Landscape - Unlike Home Depot, Walmart has indicated it may need to raise prices to cope with tariff-related costs, with CEO Doug McMillon acknowledging the pressure on their business [4]. - President Trump criticized Walmart for not absorbing tariff costs, suggesting that the company should maintain its profit margins without passing costs to consumers [5][6]. - The White House supports Trump's stance that foreign countries should bear the burden of tariffs, emphasizing that businesses should not pass these costs onto consumers [5][6]. Group 3: Broader Economic Context - Trump's administration has implemented sweeping tariffs, with rates of 10% on most imports and up to 30% on goods from China, which has led to increased scrutiny on how companies manage their pricing strategies [9][10]. - The President's comments reflect a shift in his approach, as he previously criticized price control proposals, now advocating for businesses to absorb tariff costs [9].

Elon Musk has said he will still be CEO of Tesla in five years' time —unless he dies. In a video interview at the Qatar Economic Forum in Doha on Tuesday, the billionaire said he was committed to leading Tesla until at least the end of the decade, and would only stop "if I'm dead."His comments come as doubts have emerged about Musk's future at the EV giant, which has become a target for protests and vandalism over Musk's work cutting the federal workforce with DOGE. In a combative interview with Bloomberg ...

Core Insights - Orkin's 2025 Top 50 Mosquito Cities List highlights Los Angeles as the top city for mosquito activity for the fourth consecutive year, with Detroit, Cleveland, and Denver making significant gains in the rankings [1][3][5] Summary by Category Mosquito Activity Rankings - The rankings are based on the number of new residential mosquito treatments performed by Orkin from April 2024 to March 2025 [2][4] - The top five cities for mosquito activity are Los Angeles, Chicago, New York, Atlanta, and Detroit, with Detroit making its first appearance in the top rankings [3][5] Geographic Trends - Northern cities like Detroit, Cleveland, and Denver are experiencing increased mosquito pressure as temperatures rise, indicating a shift in mosquito activity patterns [3][6] - California remains a significant area for mosquito activity, with five cities in the Top 50, including Los Angeles, San Francisco, Sacramento, San Diego, and Fresno [3][6] Health Implications - Mosquitoes pose a major health threat, responsible for over 600,000 malaria-related deaths annually and transmitting diseases such as West Nile virus and Zika virus [6] - Orkin emphasizes the importance of proactive mosquito control measures to safeguard public health [7] Community Initiatives - Orkin is launching the "Mosquitoes Don't Deserve a Drop" campaign in partnership with the American Red Cross, pledging to donate $25 for every mosquito control service purchased, up to $250,000 [7] - The campaign aims to maintain a healthy blood supply while encouraging homeowners to take preventive measures against mosquito-borne illnesses [7] Preventive Measures - Homeowners are encouraged to adopt simple preventive measures to reduce mosquito activity, summarized by the acronym BITE [8][11]

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Bitfarms Ltd. (NASDAQ: BITF) securities between March 21, 2023 and December 9, 2024. Bitfarms operates integrated Bitcoin (also referred to as “BTC”) data centers in Canada, the U.S., Paraguay, and Argentina. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegation ...

公开信息显示，科创半导体ETF(588170)跟踪上证科创板半导体材料设备主题指数，囊括科创板中半导 体设备和半导体材料细分领域的硬科技公司。半导体设备和材料行业是重要的国产替代领域，具备国产 化率较低、国产替代天花板较高属性，充分受益于人工智能革命下的半导体需求扩张。 国信证券认为，全球和中国半导体销售额均已连续六个季度实现同比正增长，除AI带来的增量外，下 游各行业去库周期已完成，其中工业库存周期靠后，处于去库完成后复苏的初期，TI1Q25营收在连续 九个季度同比下降后首季同比转正，其表示工业呈现广泛复苏，所有终端客户库存均处于低位；中芯国 际1Q25工业和汽车收入表现强劲，同比增长75.2%，环比增长22.7%。从A股半导体公司业绩来看，整 体收入连续七个季度同比正增长，在统计的146家公司中，2024/2025年收入创季度新高的有58/21家； 1Q25毛利率和净利率均同环比提高。该机构认为，随着收入规模效应显现，半导体板块利润改善幅度 将大于收入，看好板块利润修复逻辑。 5月19日早盘，A股全线小幅低开。上证指数开盘报3365.88点，跌0.05%。深证成指开盘报10171.29点， 跌0.08%。 ...

BOULDER, CO, May 16, 2025 (GLOBE NEWSWIRE) -- FST Corp. (Nasdaq: KBSX), a leading manufacturer and marketer of steel and graphite golf shafts and a provider of other golf-related services, today announced that, for the fiscal year ended December 31, 2024, the Company had revenue of $36,499,644, a 27 percent increase compared with revenue of $28,730,549 for the fiscal year ended December 31, 2023. The Company had a net loss of $3,235,175, or $(.09) per share, for fiscal 2024, a 49 percent increase compared w ...